Pharmaxis Receives Approval to Market Bronchitol in the EU
Release Date: 20/04/2012 12:00am
Pharmaceutical company Pharmaxis (ASX: PXS) is pleased to announce it has received Marketing Authorisation for Bronchitol from the European Commission. The licence allows the new cystic fibrosis treatment to be made available to patients aged 18 and over throughout the European Union.
Pharmaxis CEO Dr Alan Robertson said, “This is a very significant event, which means that patients living with cystic fibrosis in Europe will now be able to receive the proven clinical benefits of Bronchitol.”
Bronchitol will be made available across 29 European countries at an average ex-factory price of approximately 20-25 Euros per day. CF patients in Germany and the UK, where there is no requirement for pricing and reimbursement approval before launch, will be first to benefit from Bronchitol. These two countries make up 40% of the European market by value. Pharmaxis expects stock to be available for sale in Europe by mid May ahead of the official launch of the product, which will take place at the European Cystic Fibrosis Symposium in Dublin from 6th - 9th June 2012.
Categories: News and Media